MX2007004264A - Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares. - Google Patents

Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.

Info

Publication number
MX2007004264A
MX2007004264A MX2007004264A MX2007004264A MX2007004264A MX 2007004264 A MX2007004264 A MX 2007004264A MX 2007004264 A MX2007004264 A MX 2007004264A MX 2007004264 A MX2007004264 A MX 2007004264A MX 2007004264 A MX2007004264 A MX 2007004264A
Authority
MX
Mexico
Prior art keywords
ocular diseases
inhibitors
jun
terminal kinases
glaucomatous retinopathy
Prior art date
Application number
MX2007004264A
Other languages
English (en)
Inventor
Abbot F Clark
Iok-Hou Pang
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MX2007004264A publication Critical patent/MX2007004264A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen composiciones y metodos para el tratamiento de glaucoma y otras enfermedades oculares. Las composiciones y metodos estan particularmente dirigidos al uso de lnhibidores de cinasas Jura N-terminales (JNK), tales como SP600125 en el tratamiento de glaucoma y otras enfermedades oculares.
MX2007004264A 2004-10-29 2005-10-27 Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares. MX2007004264A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62375504P 2004-10-29 2004-10-29
PCT/US2005/038825 WO2006050045A2 (en) 2004-10-29 2005-10-27 Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases

Publications (1)

Publication Number Publication Date
MX2007004264A true MX2007004264A (es) 2007-06-15

Family

ID=35828365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004264A MX2007004264A (es) 2004-10-29 2005-10-27 Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.

Country Status (13)

Country Link
US (2) US20060094753A1 (es)
EP (2) EP1804790A2 (es)
JP (1) JP2008518922A (es)
KR (1) KR101234518B1 (es)
CN (2) CN102166358A (es)
AR (1) AR051472A1 (es)
AU (1) AU2005302511B2 (es)
BR (1) BRPI0518247A2 (es)
CA (1) CA2582316C (es)
MX (1) MX2007004264A (es)
TW (1) TWI377940B (es)
WO (1) WO2006050045A2 (es)
ZA (1) ZA200703990B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US20080051319A1 (en) * 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP2010254672A (ja) 2009-03-30 2010-11-11 Santen Pharmaceut Co Ltd ＪＮＫ（ｃ−Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを有効成分として含有する網膜疾患の予防または治療剤
US20120077753A1 (en) * 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US20130288981A1 (en) * 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
PL3013353T3 (pl) * 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
ES2949982T3 (es) * 2014-06-26 2023-10-04 Xigen Inflammation Ltd Inhibidores peptídicos permeables en células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis
CN109303782A (zh) * 2018-10-24 2019-02-05 厦门大学 Jnk-in-8在制备干性年龄相关性黄斑变性的神经保护剂中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO2000021531A1 (fr) * 1998-10-13 2000-04-20 Kyowa Hakko Kogyo Co., Ltd. Medicaments pour maladies oculaires
JP2002532503A (ja) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー プロテインキナーゼ阻害剤としての４，５−ピラジノオキシンドール
CA2354510A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
KR20010101266A (ko) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 Ｊｎｋ 단백질 키나제의 억제제로서의 4-아릴옥신돌
DE60041763D1 (de) * 1999-04-23 2009-04-23 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
EP1218369B1 (en) 1999-08-13 2008-07-23 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
NZ517578A (en) * 1999-08-19 2004-02-27 Signal Pharm Inc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
WO2001058448A1 (fr) * 2000-02-09 2001-08-16 Shionogi & Co., Ltd. Inhibiteur d'apoptose
AU2001241778A1 (en) * 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1193256A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
JP2002302445A (ja) * 2001-02-02 2002-10-18 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
WO2002062792A1 (fr) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
AU2002236988A1 (en) * 2001-02-06 2002-08-19 Novartis Ag Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
JP4535680B2 (ja) 2001-04-16 2010-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規１ｈ−インダゾール化合物
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
EP1426050A4 (en) * 2001-08-23 2005-05-25 Takeda Pharmaceutical INHIBITORS OF JNK
NZ531378A (en) 2001-09-19 2006-11-30 Aventis Pharma S Indolizines as kinase protein inhibitors suitable for treating solid tumours
ATE465153T1 (de) * 2002-02-28 2010-05-15 Eisai R&D Man Co Ltd Neue indazolverbindungen mit kondensiertem ring
CN1668733A (zh) * 2002-05-30 2005-09-14 细胞基因公司 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法
AU2003251721A1 (en) * 2002-06-14 2003-12-31 Laboratoires Serono Sa Azole methylidene cyanide derivatives and their use as protein kinase modulators
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20040092568A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
US20080044815A1 (en) * 2003-05-30 2008-02-21 Paul Michael Watt Genetic Screen for Interaction Interface Mapping
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma

Also Published As

Publication number Publication date
US20060094753A1 (en) 2006-05-04
WO2006050045A3 (en) 2006-12-07
ZA200703990B (en) 2008-09-25
CN101048156A (zh) 2007-10-03
KR20070070208A (ko) 2007-07-03
CN101048156B (zh) 2011-06-15
JP2008518922A (ja) 2008-06-05
CA2582316A1 (en) 2006-05-11
CN102166358A (zh) 2011-08-31
WO2006050045A2 (en) 2006-05-11
BRPI0518247A2 (pt) 2008-11-11
US20100280089A1 (en) 2010-11-04
AU2005302511A1 (en) 2006-05-11
CA2582316C (en) 2012-04-03
AU2005302511B2 (en) 2011-07-14
EP1804790A2 (en) 2007-07-11
EP2248521A1 (en) 2010-11-10
KR101234518B1 (ko) 2013-02-19
TWI377940B (en) 2012-12-01
TW200621236A (en) 2006-07-01
AR051472A1 (es) 2007-01-17

Similar Documents

Publication Publication Date Title
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
HK1113569A1 (en) Pyrazolo
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
TW200633980A (en) Pyridones useful as inhibitors of kinases
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
TW200733964A (en) (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
GEP20094780B (en) Prostaglandin nitrooxyderivatives
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
HK1116349A1 (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
MX2007007032A (es) Compuestos de aminopirimidina y metodos de uso.
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
TW200745088A (en) Benzimidazoles useful as inhibitors of protein kinases
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen

Legal Events

Date Code Title Description
FG Grant or registration